Anticoagulants tied to higher osteoporosis risk, lower bone mineral density

 

Bone density and quality in patients treated with direct-acting oral anticoagulants versus warfarin

Author links open overlay panelJeferson ZanovelliNalevaikoaJúlia Vieira ObergerMarquesbMatheus FelipeOliveiracArthur William PassosRaetschcGustavo LenciMarquesaRicardo RasmussenPetterledCarolina AguiarMoreirabVictória Zeghbi CochenskiBorbab

DOI: https://doi.org/10.1016/j.bone.2021.116000

Highlights

•

Prolonged use of warfarin seems to be a risk factor for osteoporosis.

•

Direct-acting oral anticoagulants (DOACs) are therapeutic alternatives to warfarin.

•

Few studies have evaluated the effects of DOACs on bone mass and quality.

•

Observational study including patients using oral anticoagulants for >1 year.

•

Oral anticoagulants negatively affect bone density and quality.

Abstract

Introduction

Direct-acting oral anticoagulants (DOACs) are therapeutic alternatives to warfarin that act independently of vitamin K, thus not affecting bone matrix formation. The aim of this study was to compare bone mineral density (BMD) and microarchitecture in patients treated with DOACs versus warfarin.

Methods

Cross-sectional, observational study in patients using oral anticoagulants for >1 year and a paired control group (CG). Based on the type of anticoagulant used, the patients were grouped into a DOAC (DOACG) or warfarin (WG) group. All patients filled out a questionnaire and underwent BMD evaluation and trabecular bone score (TBS) measurement.

Results

In all, 150 patients were included (50 patients in each group). The mean age was 60.49 ± 7.48 years, and most participants were men (64%). The most frequent comorbidities were hypertension, dyslipidemia, and hyperglycemia (comparison between groups p > 0.05). Low bone mass was diagnosed in 42%, 50%, and 66% of the patients in the CG, DOACG, and WG, respectively (p = 0.012). On logistic regression analysis, BMD was associated with body mass index (BMI; odds ratio [OR] 0.846, 95% confidence interval [CI] 0.763–0.926, p = 0.001), creatinine level (OR 0.024, 95%CI 0.001–0.434, p = 0.017), and TBS value (OR 17.777, 95%CI 4.526–96.903, p = 0.000). The mean TBS decreased progressively from the CG to the DOACG and WG (1.328 ± 0.112, 1.264 ± 0.138, and 1.203 ± 0.112, respectively, p < 0.001). On multivariate linear regression, negative predictors of TBS included warfarin use (−0.06, 95%CI -0.11 to −0.02, p = 0.006), BMI (−0.01, 95%CI -0.01 to −0.00, p < 0.001), and hyperglycemia (−0.07, 95%CI -0.11 to −0.03, p = 0.003), while positive predictors were an active IPAQ classification (0.06, 95%CI 0.01–0.11, p = 0.029) and family history of hip fracture (0.07, 95%CI 0.01–0.14, p = 0.029).

Conclusion

Patients using anticoagulants have lower BMD and TBS values compared with controls. This negative effect on bone was more pronounced with warfarin, but was also seen with DOACs.

https://www.sciencedirect.com/science/article/abs/pii/S8756328221001629